Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 63909J108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Parag Mallick 13D/A | 17.6% |
3/4/2026
Event 3/2/2026
|
||
| Patel Sujal M 13D/A | 16.3% |
3/4/2026
Event 3/2/2026
|
||
|
Perceptive Advisors LLC
13D/A
|
9.1% |
8/14/2026
Event 6/30/2026
|
||
| Perceptive Advisors LLC | 9.1% | |||
| Joseph Edelman | 9.1% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 9.1% | |||
| C2 Life Sciences LLC | 0.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
|
AH Bio Fund II, L.P.
13D/A
|
4.9% |
9/11/2026
Event 9/9/2026
|
||
| AH Bio Fund II, L.P. | 4.5% | |||
| AH Equity Partners Bio II, L.L.C. | 4.5% | |||
| Andreessen Horowitz LSV Fund II, L.P. | 0.4% | |||
| AH Equity Partners LSV II, L.L.C. | 0.4% | |||
| Marc L. Andreessen | 4.9% | |||
| Benjamin A. Horowitz | 4.9% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 13.5 k | $23.2 k |
| 2026 Q2 | 95 | 50.1 M | $93.7 M |
| 2026 Q1 | 83 | 54.3 M | $211 M |
| 2025 Q4 | 70 | 58.5 M | $114 M |
| 2025 Q3 | 69 | 57.9 M | $48.9 M |
| 2025 Q2 | 74 | 59.8 M | $43.3 M |
| 2025 Q1 | 91 | 62.8 M | $54.0 M |
| 2024 Q4 | 89 | 63.9 M | $107 M |
| 2024 Q3 | 87 | 64.2 M | $183 M |
| 2024 Q2 | 83 | 64.4 M | $151 M |
| 2024 Q1 | 79 | 64.1 M | $189 M |
| 2023 Q4 | 82 | 64.0 M | $191 M |
| 2023 Q3 | 80 | 45.1 M | $142 M |
| 2023 Q2 | 79 | 44.8 M | $173 M |
| 2023 Q1 | 81 | 44.5 M | $123 M |
| 2022 Q4 | 84 | 46.8 M | $84.2 M |
| 2022 Q3 | 89 | 56.5 M | $120 M |
| 2022 Q2 | 84 | 57.5 M | $155 M |
| 2022 Q1 | 87 | 56.1 M | $244 M |
| 2021 Q4 | 91 | 68.8 M | $283 M |
| 2021 Q3 | 77 | 41.0 M | $245 M |
| 2021 Q2 | 61 | 47.9 M | $470 M |